Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab

Atsushi Ogata, Noriko Umegaki, Ichiro Katayama, Atsushi Kumanogoh, Toshio Tanaka

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Psoriatic arthritis (PsA) is considered as one of the seronegative spondylarthropathies. Like rheumatoid arthritis (RA), the increased production of interleukin (IL)-6 suggests a pathogenic role of IL-6 in PsA. However, whether humanized anti-IL-6 receptor antibody such as tocilizumab (TCZ) might be effective for PsA as well as RA has yet to be determined. We report herein two cases of PsA treated using TCZ. Although, TCZ treatment resulted in disappearance of serum CRP in both patients, arthritis and skin lesions were not improved despite 6-month administration of TCZ. In contrast, tumor necrosis factor (TNF) inhibitor proved effective against arthritis and skin lesions in these patients. Collectively, these findings not only indicate that IL-6 has distinct pathological roles in RA and PsA, but also suggest that TNF inhibitor therapy (but not TCZ) is effective for arthritis and skin lesions of PsA.

Original languageEnglish
Pages (from-to)85-87
Number of pages3
JournalJoint Bone Spine
Volume79
Issue number1
DOIs
Publication statusPublished - 2012 Jan
Externally publishedYes

Fingerprint

Psoriatic Arthritis
Arthritis
Interleukin-6
Rheumatoid Arthritis
Skin
Therapeutics
Tumor Necrosis Factor-alpha
Interleukin-6 Receptors
Spondylarthropathies
tocilizumab
Antibodies
Serum

Keywords

  • Psoriatic Arthritis
  • Tocilizumab

ASJC Scopus subject areas

  • Rheumatology

Cite this

Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. / Ogata, Atsushi; Umegaki, Noriko; Katayama, Ichiro; Kumanogoh, Atsushi; Tanaka, Toshio.

In: Joint Bone Spine, Vol. 79, No. 1, 01.2012, p. 85-87.

Research output: Contribution to journalArticle

Ogata, Atsushi ; Umegaki, Noriko ; Katayama, Ichiro ; Kumanogoh, Atsushi ; Tanaka, Toshio. / Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. In: Joint Bone Spine. 2012 ; Vol. 79, No. 1. pp. 85-87.
@article{94eebf579d3941738cba1339246ec8b0,
title = "Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab",
abstract = "Psoriatic arthritis (PsA) is considered as one of the seronegative spondylarthropathies. Like rheumatoid arthritis (RA), the increased production of interleukin (IL)-6 suggests a pathogenic role of IL-6 in PsA. However, whether humanized anti-IL-6 receptor antibody such as tocilizumab (TCZ) might be effective for PsA as well as RA has yet to be determined. We report herein two cases of PsA treated using TCZ. Although, TCZ treatment resulted in disappearance of serum CRP in both patients, arthritis and skin lesions were not improved despite 6-month administration of TCZ. In contrast, tumor necrosis factor (TNF) inhibitor proved effective against arthritis and skin lesions in these patients. Collectively, these findings not only indicate that IL-6 has distinct pathological roles in RA and PsA, but also suggest that TNF inhibitor therapy (but not TCZ) is effective for arthritis and skin lesions of PsA.",
keywords = "Psoriatic Arthritis, Tocilizumab",
author = "Atsushi Ogata and Noriko Umegaki and Ichiro Katayama and Atsushi Kumanogoh and Toshio Tanaka",
year = "2012",
month = "1",
doi = "10.1016/j.jbspin.2011.06.011",
language = "English",
volume = "79",
pages = "85--87",
journal = "Revue du Rhumatisme (English Edition)",
issn = "1169-8446",
publisher = "Elsevier Masson",
number = "1",

}

TY - JOUR

T1 - Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab

AU - Ogata, Atsushi

AU - Umegaki, Noriko

AU - Katayama, Ichiro

AU - Kumanogoh, Atsushi

AU - Tanaka, Toshio

PY - 2012/1

Y1 - 2012/1

N2 - Psoriatic arthritis (PsA) is considered as one of the seronegative spondylarthropathies. Like rheumatoid arthritis (RA), the increased production of interleukin (IL)-6 suggests a pathogenic role of IL-6 in PsA. However, whether humanized anti-IL-6 receptor antibody such as tocilizumab (TCZ) might be effective for PsA as well as RA has yet to be determined. We report herein two cases of PsA treated using TCZ. Although, TCZ treatment resulted in disappearance of serum CRP in both patients, arthritis and skin lesions were not improved despite 6-month administration of TCZ. In contrast, tumor necrosis factor (TNF) inhibitor proved effective against arthritis and skin lesions in these patients. Collectively, these findings not only indicate that IL-6 has distinct pathological roles in RA and PsA, but also suggest that TNF inhibitor therapy (but not TCZ) is effective for arthritis and skin lesions of PsA.

AB - Psoriatic arthritis (PsA) is considered as one of the seronegative spondylarthropathies. Like rheumatoid arthritis (RA), the increased production of interleukin (IL)-6 suggests a pathogenic role of IL-6 in PsA. However, whether humanized anti-IL-6 receptor antibody such as tocilizumab (TCZ) might be effective for PsA as well as RA has yet to be determined. We report herein two cases of PsA treated using TCZ. Although, TCZ treatment resulted in disappearance of serum CRP in both patients, arthritis and skin lesions were not improved despite 6-month administration of TCZ. In contrast, tumor necrosis factor (TNF) inhibitor proved effective against arthritis and skin lesions in these patients. Collectively, these findings not only indicate that IL-6 has distinct pathological roles in RA and PsA, but also suggest that TNF inhibitor therapy (but not TCZ) is effective for arthritis and skin lesions of PsA.

KW - Psoriatic Arthritis

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=84855716888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855716888&partnerID=8YFLogxK

U2 - 10.1016/j.jbspin.2011.06.011

DO - 10.1016/j.jbspin.2011.06.011

M3 - Article

VL - 79

SP - 85

EP - 87

JO - Revue du Rhumatisme (English Edition)

JF - Revue du Rhumatisme (English Edition)

SN - 1169-8446

IS - 1

ER -